Search for: "Johnson v. Monsanto Company et al"
Results 1 - 9
of 9
Sort by Relevance
|
Sort by Date
11 Aug 2021, 9:52 am
Additionally, Monsanto admitted that it never conducted any long-term carcinogenicity studies on any of the formulations that it’s sold in the United States.Holding:The Court held that the Federal Insecticide, Fungicide, and Rodenticide Act (FIRRA) 7 U.S.C. ch. 6 §136 et al. does not preempt state law. [read post]
30 Apr 2012, 11:19 am
James III, et al. [read post]
10 May 2010, 2:59 am
There is not enough local food to meet the demand, nor enough farmers growing local food, nor companies in the business of processing local food. [read post]
10 Mar 2010, 5:22 am
KG et al. v. [read post]
10 Mar 2010, 5:22 am
KG et al. v. [read post]
30 May 2008, 9:09 am
: (Spicy IP), India: DCGI preparing document to implement patent-registration linkage: (Spicy IP), New Zealand: Generic pharmaceutical companies taking advantage of NZ IP laws and medicines regulations: (International Law Office), Uganda: Cipla licenses ARV technology into Uganda: (Afro-IP), US: Money saved through generic prescriptions: (GenericsWeb), US: Government plans to keep close tab on drug patent settlements: (GenericsWeb), US: FTC reports 14 deals to delay generics in 2007:… [read post]
2 May 2008, 7:00 am
: (Patent Baristas), US: How to avoid a permanent injunction: the lessons of Amgen v Hoffman-LaRoche: (Patent Docs), US: Jarvik Heart’s PTE request based on PMA shell/module submission dates flatlines; ruling on initiation of PTE ‘review period’ mirrors FDA policy for ‘fast track’ products: (FDA Law Blog) Pharma & Biotech - Products Kytril (Granisetron) – Exclusivity ‘parking’ still… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
4 Apr 2008, 1:00 am
, (Ars Technica), (Patent Prospector), (Washington State Patent Law Blog), (IP Law Observer), (PLI), (PLI), (IP Updates), (Patent Docs), (Peter Zura’s 271 Patent Blog), (The Invent Blog), (IP Spotlight), (Just a Patent Examiner), (Techdirt), (Patent Baristas), (IPBiz), (IPBiz), (Patently-O), (IAM), (IP ThinkTank), (Against Monopoly), (Against Monopoly), (IP Law360), (Hal Wegner), (Ladas & Parry), Global Global - General Virtual monopoly – four strategic choices:… [read post]
